Accès gratuit
Numéro |
Med Sci (Paris)
Volume 22, Numéro 2, Février 2006
|
|
---|---|---|
Page(s) | 178 - 182 | |
Section | M/S revues | |
DOI | https://doi.org/10.1051/medsci/2006222178 | |
Publié en ligne | 15 février 2006 |
- Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365 : 687–701. [Google Scholar]
- Bastian BC. Understanding the progression of melanocytic neoplasia using genomic analysis : from fields to cancer. Oncogene 2003; 22 : 3081–6. [Google Scholar]
- Nelson MA, Radmacher MD, Simon R, et al. Chromosome abnormalities in malignant melanoma : clinical significance of nonrandom chromosome abnormalities in 206 cases. Cancer Genet Cytogenet 2000; 122 : 101–9. [Google Scholar]
- Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353 : 2135–47. [Google Scholar]
- Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000; 60 : 1968–73. [Google Scholar]
- Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003; 163 : 1765–70. [Google Scholar]
- Van Dijk M, Sprenger S, Rombout P, et al. Distinct chromosomal aberrations in sinonasal mucosal melanoma as detected by comparative genomic hybridization. Genes Chromosomes Cancer 2003; 36 : 151–8. [Google Scholar]
- Chudnovsky Y, Adams AE, Robbins PB, et al. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 2005; 37 : 745–9. [Google Scholar]
- Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002; 62 : 3200–6. [Google Scholar]
- Hoglund M, Gisselsson D, Hansen GB, et al. Dissecting karyotypic patterns in malignant melanomas : temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004; 108 : 57–65. [Google Scholar]
- Balazs M, Adam Z, Treszl A, et al. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 2001; 46 : 222–32. [Google Scholar]
- Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417 : 949–54. [Google Scholar]
- Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004; 10 : 1753–7. [Google Scholar]
- Sharma A, Trivedi NR, Zimmerman MA, et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005; 65 : 2412–21. [Google Scholar]
- Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004; 64 : 2338–42. [Google Scholar]
- Laud K, Kannengiesser C, Avril MF, et al. BRAF as a melanoma susceptibility candidate gene ? Cancer Res 2003; 63 : 3061–5. [Google Scholar]
- Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma : a possible association with clinical outcome. Clin Cancer Res 2003; 9 : 3362–8. [Google Scholar]
- Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95 : 1878–90. [Google Scholar]
- Davison JM, Rosenbaum E, Barrett TL, et al. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 2005; 103 : 788–92. [Google Scholar]
- Hingorani SR, Jacobetz MA, Robertson GP, et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003; 63 : 5198–202. [Google Scholar]
- Bollag G, Freeman S, Lyons JF, Post LE. Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 2003; 4 : 1436–41. [Google Scholar]
- Cruz F, Rubin BP, Wilson D, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003; 63 : 5761–6. [Google Scholar]
- Schaffer JV, Bolognia JL. The melanocortin-1 receptor : red hair and beyond. Arch Dermatol 2001; 137 : 1477–1485. [Google Scholar]
- Sturm RA, Teasdale RD, Box NF. Human pigmentation genes : identification, structure and consequences of polymorphic variation. Gene 2001; 277 : 49–62. [Google Scholar]
- Matichard E, Verpillat P, Meziani R, et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 2004; 41 : e13. [Google Scholar]
- Radhi JM. Malignant melanoma arising from nevi, p53, p16, and Bcl-2 : expression in benign versus malignant components. J Cutan Med Surg 1999; 3 : 293–7. [Google Scholar]
- Soto JL, Cabrera CM, Serrano S, Lopez-Nevot MA. Mutation analysis of genes that control the G1/S cell cycle in melanoma : TP53, CDKN1A, CDKN2A, and CDKN2B. BMC Cancer 2005; 5 : 36. [Google Scholar]
- Mikhail M, Velazquez E, Shapiro R, et al. PTEN expression in melanoma : relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 2005; 11 : 5153–7. [Google Scholar]
- Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16 : 64–7. [Google Scholar]
- Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma : a global perspective. Arch Dermatol 2001; 137 : 1493–6. [Google Scholar]
- Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264 : 436–40. [Google Scholar]
- Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368 : 753–6. [Google Scholar]
- Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8 : 15–21. [Google Scholar]
- Chin L. The genetics of malignant melanoma : lessons from mouse and man. Nat Rev Cancer 2003; 3 : 559–70. [Google Scholar]
- Tsao H, Zhang X, Kwitkiwski K, et al. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 2000; 136 : 1118–22. [Google Scholar]
- Gillanders E, Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003; 73 : 301–13. [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.